99 related articles for article (PubMed ID: 2696307)
21. Clobetasol--a potent new topical corticosteroid.
Med Lett Drugs Ther; 1986 Jun; 28(715):57-9. PubMed ID: 3520267
[No Abstract] [Full Text] [Related]
22. Heterogeneous populations of class II MHC+ cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells.
Meunier L; Gonzalez-Ramos A; Cooper KD
J Immunol; 1993 Oct; 151(8):4067-80. PubMed ID: 8409386
[TBL] [Abstract][Full Text] [Related]
23. Skin application of the nonsteroidal anti-inflammatory drug ketoprofen downmodulates the antigen-presenting ability of Langerhans cells in mice.
Atarashi K; Kabashima K; Akiyama K; Tokura Y
Br J Dermatol; 2008 Aug; 159(2):306-13. PubMed ID: 18565185
[TBL] [Abstract][Full Text] [Related]
24. Participation of epidermal langerhans cells in human pathology and their potential as targets for drug development: a review of literature.
Ayala-García I; Hernández-Segura AM; Castell-Rodríguez A; Alvarez Pérez SJ; Téllez BH; Ramírez-González MD
Proc West Pharmacol Soc; 2005; 48():13-20. PubMed ID: 16416652
[TBL] [Abstract][Full Text] [Related]
25. The effects of topical and systemic glucocorticosteroids on DNA synthesis in different tissues of the hairless mouse.
Marshall RC; Burrows M; Brookes LG; du Vivier A
Br J Dermatol; 1981 Nov; 105(5):517-20. PubMed ID: 7295568
[TBL] [Abstract][Full Text] [Related]
26. Peristomal dermatoses: a novel indication for topical steroid lotions.
Lyon CC; Smith AJ; Griffiths CE; Beck MH
J Am Acad Dermatol; 2000 Oct; 43(4):679-82. PubMed ID: 11004626
[TBL] [Abstract][Full Text] [Related]
27. Human epidermal Langerhans cells differ from monocyte-derived Langerhans cells in CD80 expression and in secretion of IL-12 after CD40 cross-linking.
Peiser M; Wanner R; Kolde G
J Leukoc Biol; 2004 Sep; 76(3):616-22. PubMed ID: 15178702
[TBL] [Abstract][Full Text] [Related]
28. Pimecrolimus does not affect Langerhans cells in murine epidermis.
Meingassner JG; Kowalsky E; Schwendinger H; Elbe-Bürger A; Stütz A
Br J Dermatol; 2003 Oct; 149(4):853-7. PubMed ID: 14616380
[TBL] [Abstract][Full Text] [Related]
29. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT.
Guichard A; Humbert P; Tissot M; Muret P; Courderot-Masuyer C; Viennet C
Int J Pharm; 2015 Feb; 479(2):422-9. PubMed ID: 25556056
[TBL] [Abstract][Full Text] [Related]
30. Nadifloxacin downmodulates antigen-presenting functions of epidermal Langerhans cells and keratinocytes.
Murata K; Sugita K; Kobayashi M; Kabashima K; Tokura Y
J Dermatol Sci; 2006 May; 42(2):91-9. PubMed ID: 16431082
[TBL] [Abstract][Full Text] [Related]
31. Quantifying anti-inflammatory agents' potency by measurement of response to dinitrochlorobenzene challenge.
Rees JL; Matthews JN; Friedmann PS
J Dermatol Sci; 1992 Jul; 4(1):1-5. PubMed ID: 1390452
[TBL] [Abstract][Full Text] [Related]
32. Intrinsic potencies of novel thiol ester corticosteroids RS-85095 and RS-21314 as compared with clobetasol 17-propionate and fluocinonide.
Ong JT; Poulsen BJ; Akers WA; Scholtz JR; Genter FC; Kertesz DJ
Arch Dermatol; 1989 Dec; 125(12):1662-5. PubMed ID: 2589861
[TBL] [Abstract][Full Text] [Related]
33. Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of Langerhans cell-dependent function is followed by the appearance of T6- Dr+ cells that enhance epidermal alloantigen presentation.
Cooper KD; Fox P; Neises G; Katz SI
J Immunol; 1985 Jan; 134(1):129-37. PubMed ID: 3964811
[TBL] [Abstract][Full Text] [Related]
34. A study of systemic and topical effects of topical steroid application through the comparison of two application schedules.
Fukaya Y; Masutani M; Koyama Y; Takahashi H; Ueda H
J Dermatol; 1990 Jan; 17(1):28-33. PubMed ID: 2329214
[TBL] [Abstract][Full Text] [Related]
35. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin.
Kolbe L; Kligman AM; Schreiner V; Stoudemayer T
Skin Res Technol; 2001 May; 7(2):73-7. PubMed ID: 11393207
[TBL] [Abstract][Full Text] [Related]
36. Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action.
Norris JF; Ilderton E; Yardley HJ; Summerly R; Forster S
Br J Dermatol; 1984 Jul; 111 Suppl 27():195-203. PubMed ID: 6743552
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of anthralin inflammation. 2. Effect of pretreatment with glucocorticoids, anthralin and removal of stratum corneum.
Lawrence CM; Shuster S
Br J Dermatol; 1985 Jul; 113(1):117-22. PubMed ID: 4015968
[TBL] [Abstract][Full Text] [Related]
38. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation.
Oussedik E; Saleem MD; Feldman SR
J Drugs Dermatol; 2017 Oct; 16(10):972-975. PubMed ID: 29036250
[TBL] [Abstract][Full Text] [Related]
39. Modulation of expression of epidermal Langerhans cell properties following in situ exposure to glucocorticosteroids.
Berman B; France DS; Martinelli GP; Hass A
J Invest Dermatol; 1983 Mar; 80(3):168-71. PubMed ID: 6338128
[TBL] [Abstract][Full Text] [Related]
40. Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin.
Ali MA; Thrower SL; Hanna SJ; Coulman SA; Birchall JC; Wong FS; Dayan CM; Tatovic D
Immunology; 2015 Nov; 146(3):411-22. PubMed ID: 26293297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
